The evolution of commercial drug delivery technologies

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

RNA-Guided Human Genome Engineering via Cas9

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210

Stimuli-responsive nanocarriers for drug delivery

Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Liposomal drug delivery systems: From concept to clinical applications

Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839

Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792

Drug Delivery Systems: Entering the Mainstream

Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552

Generation of germline-competent induced pluripotent stem cells

Okita, K., Ichisaka, T., & Yamanaka, S. (2007) · Nature · doi:10.1038/nature05934 · Cited by 4,438

The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems

Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,996

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834

COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,743

Transdermal drug delivery

Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,691

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533

Long-Circulating and Target-Specific Nanoparticles: Theory to Practice

Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,521

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207

Knocking down barriers: advances in siRNA delivery

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115

Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release

Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678

Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries

Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572

Phage antibodies: filamentous phage displaying antibody variable domains

McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427

Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing

Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383

Toxicity of cationic lipids and cationic polymers in gene delivery

Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Development of therapeutic antibodies for the treatment of diseases

Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,235

Drug Solubility: Importance and Enhancement Techniques

Savjani, K. T., Gajjar, A. K., & Savjani, J. (2012) · ISRN Pharmaceutics · doi:10.5402/2012/195727 · Cited by 2,155

The Future of Peptide‐based Drugs

Craik, D. J., Fairlie, D. P., Liras, S. I., & Price, D. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 2,034

Drug Delivery and Targeting

Hillery, A. M., Lloyd, A. W., & Swarbrick, J. (2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030

Generation of Functional Human Pancreatic β Cells In Vitro

Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012

The COVID-19 vaccine development landscape

Le, T. T., Andreadakis, Z., Kumar, A., Román, R. G., Tollefsen, S., Saville, M. K., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 2,002

Therapeutic peptides: Historical perspectives, current development trends, and future directions

Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879

Rational design of cationic lipids for siRNA delivery

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822

How were new medicines discovered?

Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785

New Methods of Drug Delivery

Langer, R. (1990) · Science · doi:10.1126/science.2218494 · Cited by 1,778

Nanoparticles in the clinic: an update

Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766

Drug delivery systems: An updated review

Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671

Solid dispersion of poorly water‐soluble drugs: Early promises, subsequent problems, and recent breakthroughs

Serajuddin, A. T. M. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980403l · Cited by 1,661

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636

Chemistry for peptide and protein PEGylation

Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,628

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Papahadjopoulos, D., Allen, T. M., Gabizón, A., Mayhew, E. G., Matthay, K. K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasiç, D. D., & Redemann, C. T. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,621

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512

Skin penetration enhancers

Lane, M. E. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.040 · Cited by 1,486

Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs

Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452

Insoluble drug delivery strategies: review of recent advances and business prospects

Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406

Therapeutic antibodies: successes, limitations and hopes for the future

Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382

Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.

Abuchowski, A., Es, T. V., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358

Nanoparticles in the clinic

Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

Defining the Epidemiology of Covid-19 — Studies Needed

Lipsitch, M., Swerdlow, D. L., & Finelli, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2002125 · Cited by 1,260

Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers

Champion, J. A., Katare, Y. K., & Mitragotri, S. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.022 · Cited by 1,228

The chemical evolution of oligonucleotide therapies of clinical utility

Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216

Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141

Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. I. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,095

Development trends for human monoclonal antibody therapeutics

Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,054

Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles

Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 1,001

Pegylation

Harris, J. M., Martin, N., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913

CAR T Cell Therapy for Solid Tumors

Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Role of Particle Size in Phagocytosis of Polymeric Microspheres

Champion, J. A., Walker, A. H., & Mitragotri, S. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9562-y · Cited by 887

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

Nabel, G. J., Nabel, E. G., Yang, Z., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., & Chang, A. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11307 · Cited by 882

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869

Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery

Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B., & Gu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505405112 · Cited by 867

Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.

Wu, G. Y., & Wu, C. H. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61209-8 · Cited by 855

Pharmacokinetics of Monoclonal Antibodies

Ryman, J. T., & Meibohm, B. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 847

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 801

Antisense oligonucleotides: the next frontier for treatment of neurological disorders

Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788

Antibody-Drug Conjugates in Cancer Therapy

Sievers, E. L., & Senter, P. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 784

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780

Basics and Recent Advances in Peptide and Protein Drug Delivery

Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 771

Global Manufacturing of CAR T Cell Therapy

Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 752

Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee

Bartlett, W., Skinner, J. A., Gooding, C. R., Carrington, R., Flanagan, A. M., Briggs, T. W. R., & Bentley, G. (2005) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.87b5.15905 · Cited by 737

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733

PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs

Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733

Controlled drug delivery systems: Past forward and future back

Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 721

Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties

Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P. L., Shirasugi, N., Strobertb, E., Anderson, D., Cowan, S. R., Price, K., Naemura, J. R., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00749.x · Cited by 721

Cytokines in Cancer Immunotherapy

Lee, S. Y., & Margolin, K. A. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 718

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711

Long-term glycemic control using polymer-encapsulated human stem cell–derived beta cells in immune-competent mice

Vegas, A. J., Veiseh, O., Gürtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., Doloff, J. C., Li, J., Chen, M., Olejnik, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4030 · Cited by 710

Cancer nanomedicine: from targeted delivery to combination therapy

Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693

Advances in oral peptide therapeutics

Drucker, D. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 686

Phosphorothioates, Essential Components of Therapeutic Oligonucleotides

Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684

PEGylation of therapeutic proteins

Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681

Non-invasive delivery strategies for biologics

Anselmo, A. C., Gokarn, Y. R., & Mitragotri, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 671

Strategic Approaches to Optimizing Peptide ADME Properties

Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Tang, L., Zheng, Y., Melo, M. B., Mabardi, L., Castaño, A. P., Xie, Y., Li, N., Kudchodkar, S. B., Wong, H. C., Jeng, E. K., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4181 · Cited by 663

Antibody–drug conjugates: targeted drug delivery for cancer

Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 660

COVID-19 vaccine development and a potential nanomaterial path forward

Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 660

Advances in the delivery of RNA therapeutics: from concept to clinical reality

Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 639

Mechanism of oligonucleotide release from cationic liposomes.

Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634

Improving cancer immunotherapy through nanotechnology

Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628

Cationic liposome-mediated gene transfer.

Gao, X., & Huang, L. (1995) · PubMed · Cited by 619

A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft)

McKay, W. F., Peckham, S. M., & Badura, J. M. (2007) · International Orthopaedics · doi:10.1007/s00264-007-0418-6 · Cited by 617

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A., Custer, M. C., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2865 · Cited by 613

Driving CAR T-cells forward

Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613

On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids

Hafez, I., Maurer, N., & Cullis, P. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601

Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions

Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593

PEGylated antibodies and antibody fragments for improved therapy: a review

Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 563

Novel Drug Delivery Systems

Chien, Y. W. (1991) · CRC Press eBooks · doi:10.1201/9780367805456 · Cited by 558

Evolution of the COVID-19 vaccine development landscape

Le, T. T., Cramer, J. P., Chen, R. H., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00151-8 · Cited by 556

Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates

Vegas, A. J., Veiseh, O., Doloff, J. C., Ma, M., Tam, H. H., Bratlie, K., Li, J., Bader, A. R., Langan, E., Olejnik, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3462 · Cited by 551

Beyond natural antibodies: the power of in vitro display technologies

Bradbury, A. M., Sidhu, S. S., Dübel, S., & McCafferty, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1791 · Cited by 548

Nucleic-acid therapeutics: basic principles and recent applications

Opalinska, J., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 535

Delivery of Therapeutic Proteins

Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532

Materials for oral delivery of proteins and peptides

Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 527

Developing a new class of engineered live bacterial therapeutics to treat human diseases

Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523

Chimeric antigen receptor T-cell therapies for lymphoma

Brudno, J. N., & Kochenderfer, J. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 522

Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies

Shih, T., & Lindley, C. M. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521

The SARS-CoV-2 Vaccine Pipeline: an Overview

Chen, W., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 517

How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions

Mensink, M. A., Frijlink, H. W., Maarschalk, K. V. D. V., & Hinrichs, W. L. J. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.01.024 · Cited by 502

Cell-penetrating peptides: tools for intracellular delivery of therapeutics

Deshayes, S., Morris, M. C., Divita, G., & Heitz, F. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5109-0 · Cited by 488

Improving protein therapeutics with sustained-release formulations

Putney, S. D., & Burke, P. A. (1998) · Nature Biotechnology · doi:10.1038/nbt0298-153 · Cited by 469

Chemical Modification of siRNAs for In Vivo Use

Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 464

Mesenchymal Stem Cell: Keystone of the Hematopoietic Stem Cell Niche and a Stepping-Stone for Regenerative Medicine

Frenette, P. S., Pinho, S., Lucas, D., & Scheiermann, C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095919 · Cited by 462

Engineering bacteria for diagnostic and therapeutic applications

Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures

Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448

Givosiran: First Approval

Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 441

Biopolymer implants enhance the efficacy of adoptive T-cell therapy

Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2014) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 440

Cellular backpacks for macrophage immunotherapy

Shields, C. W., Evans, M. A., Wang, L., Baugh, N. J., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 422

Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes

Wang, X., Ishida, T., & Kiwada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.010 · Cited by 421

Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems

Villa, C. H., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.007 · Cited by 404

Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut Microbiota

Mimee, M., Tucker, A. C., Voigt, C. A., & Lu, T. K. (2015) · Cell Systems · doi:10.1016/j.cels.2015.06.001 · Cited by 387

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372

Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist

Beaumont, K. C., Webster, R., Gardner, I. B., & Dack, K. N. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489253 · Cited by 369

Marketed therapeutic antibodies compendium

Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.19931 · Cited by 368

Origin and evolution of high throughput screening

Pereira, D. A., & Williams, J. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707373 · Cited by 367

Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques

Bochenek, M. A., Veiseh, O., Vegas, A. J., McGarrigle, J. J., Qi, M., Marchese, E., Omami, M., Doloff, J. C., Mendoza-Elias, J., Nourmohammadzadeh, M., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0275-1 · Cited by 367

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

Gargett, T., Yu, W., Dotti, G., Yvon, E. S., Christo, S. N., Hayball, J. D., Lewis, I. D., Brenner, M. K., & Brown, M. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.63 · Cited by 361

Immune-mediated approaches against COVID-19

Florindo, H. F., Kleiner, R., Vaskovich‐Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi‐Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 356

Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells

Anselmo, A. C., Gupta, V., Zern, B. J., Pan, D., Zakrewsky, M., Muzykantov, V., & Mitragotri, S. (2013) · ACS Nano · doi:10.1021/nn404853z · Cited by 355

Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects

Sharma, P. C., Jain, A., Jain, S., Pahwa, R., & Yar, M. S. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756360903373350 · Cited by 354

Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes

Friend, D. S., Papahadjopoulos, D., & Debs, R. J. (1996) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00219-7 · Cited by 352

Oral insulin delivery1Abbreviations: GI, gastrointestinal; IDDM, insulin-dependent diabetes mellitus; IU, international units; NIDDM, non-insulin-dependent diabetes mellitus; PIN, phase inversion nanoencapsulation; ZOT, zona occludens toxin.1

Carino, G. P., & Mathiowitz, E. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00075-1 · Cited by 347

The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic

Zhang, W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 334

Poly(2‐ethyl‐2‐oxazoline) as Alternative for the Stealth Polymer Poly(ethylene glycol): Comparison of in vitro Cytotoxicity and Hemocompatibility

Bauer, M., Lautenschläger, C., Kempe, K., Tauhardt, L., Schubert, U. S., & Fischer, D. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201200017 · Cited by 332

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain

Chey, W. D., Webster, L. R., Sostek, M. B., Lappalainen, J., Barker, P. N., & Tack, J. F. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310246 · Cited by 328

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Frost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323

High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria

Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315

Synthetic materials at the forefront of gene delivery

Lostalé‐Seijo, I., & Montenegro, J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0039-1 · Cited by 315

A natural history of botanical therapeutics

Schmidt, B. M., Ribnicky, D., Poulev, A., Logendra, S., Cefalu, W. T., & Raskin, I. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.001 · Cited by 310

Cell-mediated delivery of nanoparticles: Taking advantage of circulatory cells to target nanoparticles

Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.050 · Cited by 310

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells

Shum, T., Omer, B. A., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0538 · Cited by 304

The rise and rise of drug delivery

Rosen, H., & Abribat, T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1721 · Cited by 296

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

Coats, S. R., Williams, M. B., Kebble, B., Dixit, R., Tseng, L., Yao, N., Tice, D. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 290

Quality cell therapy manufacturing by design

Lipsitz, Y. Y., Timmins, N. E., & Zandstra, P. (2016) · Nature Biotechnology · doi:10.1038/nbt.3525 · Cited by 287

The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282

Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study

Dlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279

Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials

Stephan, M. T., & Irvine, D. J. (2011) · Nano Today · doi:10.1016/j.nantod.2011.04.001 · Cited by 270

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & Groot, A. S. D. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270

The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal And Antiviral Drugs

Kucers, A. (1997) · Cited by 269

Solvent Effects on the Preferred Conformation of Poly(ethylene glycols)

Liu, K.-J., & Parsons, J. L. (1969) · Macromolecules · doi:10.1021/ma60011a015 · Cited by 262

Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration

Teorell, T. (1937) · Archives internationales de pharmacodynamie et de thérapie · Cited by 260

Interleukin-23 engineering improves CAR T cell function in solid tumors

Ma, X., Shou, P., Smith, C. C., Chen, Y., Du, H., Sun, C., Kren, N. P., Michaud, D. E., Ahn, S., Vincent, B. G., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0398-2 · Cited by 259

Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes

Baenziger, J., & Fiete, D. (1980) · Cell · doi:10.1016/0092-8674(80)90371-2 · Cited by 248

Nanotechnology intervention of the microbiome for cancer therapy

Song, W., Anselmo, A. C., & Huang, L. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0589-5 · Cited by 248

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Yeku, O., & Brentjens, R. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150291 · Cited by 247

Safety and immunologic effects of IL-15 administration in nonhuman primates

Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244

Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape

Endoh, T., & Ohtsuki, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.005 · Cited by 242

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 242

Current drug research on PEGylation with small molecular agents

Li, W., Zhan, P., Clercq, E. D., Lou, H., & Liu, X. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2012.07.006 · Cited by 241

Enteric coated HPMC capsules designed to achieve intestinal targeting

Cole, E. T., Scott, R. A., Connor, A. L., Wilding, I. R., Petereit, H.-U., Schminke, C., Beckert, T. E., & Cadé, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00871-7 · Cited by 241

Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications

Benizri, S., Gissot, A., Martin, A., Vialet, B., Grinstaff, M. W., & Barthélémy, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00761 · Cited by 241

Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS

Dou, H., Grotepas, C. B., McMillan, J., Destache, C. J., Chaubal, M. V., Werling, J. O., Kipp, J., Rabinow, B. E., & Gendelman, H. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900274 · Cited by 238

Anti-VEGF therapies in the clinic

Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237

Conformation of poly(ethylene oxide) in the solid state, melt and solution measured by Raman scattering

Maxfield, J., & Shepherd, I. W. (1975) · Polymer · doi:10.1016/0032-3861(75)90008-7 · Cited by 236

Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas

Kauer, T. M., de Figueiredo, J. L., Hingtgen, S., & Shah, K. (2011) · Nature Neuroscience · doi:10.1038/nn.3019 · Cited by 234

Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Prasad, V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.156 · Cited by 229

Clinical trials of Herceptin® (trastuzumab)

Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00404-4 · Cited by 227

Microneedle patches for vaccination in developing countries

Arya, J. M., & Prausnitz, M. R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.019 · Cited by 224

Injectable controlled release depots for large molecules

Schwendeman, S. P., Shah, R. B., Bailey, B. A., & Schwendeman, A. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.057 · Cited by 223

Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases

Volkman, R., & Offen, D. (2017) · Stem Cells · doi:10.1002/stem.2651 · Cited by 222

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

Eggermont, L. J., Paulis, L. E. M., Tel, J., & Figdor, C. G. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.06.007 · Cited by 218

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Chien, S., Rogge, M. C., Gisclon, L. G., Curtin, C. R., Wong, F., Natarajan, J., Williams, R. R., Fowler, C. L., Cheung, W. K., & Chow, A. T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2256 · Cited by 216

Cell-Permeable Cyclic Peptides from Synthetic Libraries Inspired by Natural Products

Hewitt, W. M., Leung, S. S. F., Pye, C. R., Ponkey, A. R., Bednarek, M. A., Jacobson, M. P., & Lokey, R. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508766b · Cited by 216

High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption

Ding, X., Stewart, M. P., Sharei, A., Weaver, J. C., Langer, R., & Jensen, K. F. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0039 · Cited by 216

The history and development of the fentanyl series

Stanley, T. H. (1992) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(92)90047-l · Cited by 214

Fecal microbiota transplantation in relapsing Clostridium difficile infection

Rohlke, F., & Stollman, N. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12453637 · Cited by 214

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy

Devaud, C., John, L. B., Westwood, J. A., Darcy, P. K., & Kershaw, M. H. (2013) · OncoImmunology · doi:10.4161/onci.25961 · Cited by 212

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

Kempf, D. J., Sham, H. L., Marsh, K. C., Flentge, C. A., Betebenner, D. A., Green, B. E., McDonald, E. J., Vasavanonda, S., Saldivar, A. C., Wideburg, N. E., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970636+ · Cited by 205

How mRNA therapeutics are entering the monoclonal antibody field

Van Hoecke, L., & Roose, K. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1804-8 · Cited by 205

Physiological Pharmaceutics: Barriers to Drug Absorption

WILSON, C. G., Washington, N., & Washington, C. (2000) · Cited by 202

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement.

Aarden, L., Ruuls, S., & Wolbink, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.011 · Cited by 198

Lipid nanoparticle delivery systems for siRNA-based therapeutics

Wan, C. P. L., Allen, T. M., & Cullis, P. R. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 198

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Povsic, T. J., Lawrence, M. G., Lincoff, A. M., Mehran, R., Rusconi, C. P., Zelenkofske, S. L., Huang, Z., Sailstad, J. M., Armstrong, P. W., Steg, P. G., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.058 · Cited by 198

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349

Polymeric Nanoparticles for Drug Delivery

Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,279

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073

Advances in drug delivery systems, challenges and future directions

Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17488 · Cited by 1,040

Recent advances in transdermal drug delivery systems: a review

Jeong, W. Y., Kwon, M., Choi, H. E., & Kim, K. S. (2021) · Biomaterials Research · doi:10.1186/s40824-021-00226-6 · Cited by 598

The Evolution of 5 Therapeutic Drug Delivery Technologies

Fang, S. J. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5162156

The Future of Drug Delivery

Gao, J., Karp, J. M., Langer, R., & Joshi, N. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.2c03003 · Cited by 297

Introduction

(2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26787-1.00001-1

Insight on the Rise and Raise of Drug Delivery with Special Emphasis on Five Classes of Therapeutics

Desavathu, M., Singh, P., Pal, A., Joshi, N., & Upadhyay, R. K. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053703 · Cited by 1

A Review of Next-Generation Drug Delivery Systems And Technologies

Sahithi, C., & Ande, P. P. (2023) · International Journal of Research in Pharmacology & Pharmacotherapeutics · doi:10.61096/ijrpp.v12.iss4.2023.289-300